轴性脊柱关节炎或银屑病关节炎患者启动阿片类药物后与长期阿片类药物使用相关的因素
研究基于英国初级保健数据库,纳入2006至2021年启动阿片类药物的成人轴性脊柱关节炎或银屑病关节炎患者,共8212例患者、10300次启动。采用混合效应logistic回归分析发现,当前吸烟、物质使用障碍、自杀/自伤史、共病纤维肌痛、较高Charlson共病指数、启动时高MME/日、加巴喷丁类药物和抗抑郁药使用与长期阿片类药物使用相关。
要点
- 当前吸烟、物质使用障碍、自杀/自伤史与长期阿片类药物使用相关。
- 共病纤维肌痛、较高Charlson共病指数、启动时高MME/日与长期使用相关。
- 加巴喷丁类药物和抗抑郁药使用与长期阿片类药物使用相关。
核心结论
- 在需要疼痛缓解的轴性脊柱关节炎或银屑病关节炎患者中,了解与长期阿片类药物使用较高风险相关的生活方式、社会人口学和处方特征,可促使及时干预如结构化药物审查和戒烟,以促进更安全处方和更好患者结局。
研究设计与样本
- 研究数据来自英国国家初级保健数据库Clinical Practice Research Datalink Gold,纳入2006年至2021年间启动阿片类药物的成人轴性脊柱关节炎或银屑病关节炎患者,且无既往癌症。
- 共识别8212例患者的10300次阿片类药物启动,其中轴性脊柱关节炎3037次,银屑病关节炎5175次。
- 长期阿片类药物使用定义为随访第一年内有≥3张阿片类药物处方在90天内开具,或阿片类药物供应≥90天。
- 采用患者水平随机截距的混合效应logistic回归模型检验个体特征与长期阿片类药物使用 odds 的关联。
主要发现
- 当前吸烟(OR: 1.62; 95%CI: 1.38,1.90)、物质使用障碍(OR: 2.34, 95%CI: 1.05,5.21)、自杀/自伤史(OR: 1.84; 95%CI: 1.13,2.99)与长期阿片类药物使用相关。
- 共病纤维肌痛(OR: 1.62; 95%CI: 1.11,2.37)、较高Charlson共病指数(高评分OR: 3.61; 95%CI: 1.69,7.71)、启动时高MME/日(OR: 1.03; 95%CI: 1.02,1.03)与长期阿片类药物使用相关。
- 加巴喷丁类药物(OR: 2.35; 95%CI: 1.75,3.16)和抗抑郁药使用(OR: 1.69; 95%CI: 1.45,1.98)与长期阿片类药物使用相关。
关键数值与推荐
- 长期阿片类药物使用定义为随访第一年内有≥3张阿片类药物处方在90天内开具,或阿片类药物供应≥90天。
- 当前吸烟OR: 1.62; 95%CI: 1.38,1.90;物质使用障碍OR: 2.34, 95%CI: 1.05,5.21;自杀/自伤史OR: 1.84; 95%CI: 1.13,2.99。
- 共病纤维肌痛OR: 1.62; 95%CI: 1.11,2.37;较高Charlson共病指数(高评分)OR: 3.61; 95%CI: 1.69,7.71;启动时高MME/日OR: 1.03; 95%CI: 1.02,1.03。
- 加巴喷丁类药物OR: 2.35; 95%CI: 1.75,3.16;抗抑郁药OR: 1.69; 95%CI: 1.45,1.98。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Up to one in five patients with axial spondyloarthritis (AxSpA) or psoriatic arthritis (PsA) newly initiated on opioids transition to long-term use within the first year. This study aimed to investigate individual factors associated with long-term opioid use among opioid new users with AxSpA/PsA. METHODS: Adult patients with AxSpA/PsA and without prior cancer who initiated opioids between 2006 and 2021 were included from Clinical Practice Research Datalink Gold, a national UK primary care database. Long-term opioid use was defined as having ≥3 opioid prescriptions issued within 90 days, or ≥90 days of opioid supply, in the first year of follow-up. Individual factors assessed included sociodemographic, lifestyle factors, medication use and comorbidities. A mixed-effects logistic regression model with patient-level random intercept was used to examine the association of individual characteristics with the odds of long-term opioid use. RESULTS: In total, 10 300 opioid initiations were identified from 8212 patients (3037 AxSpA; 5175 PsA). The following factors were associated with long-term opioid use: being a current smoker (OR: 1.62; 95%CI: 1.38,1.90), substance use disorder (OR: 2.34, 95%CI: 1.05,5.21), history of suicide/self-harm (OR: 1.84; 95%CI: 1.13,2.99), co-existing fibromyalgia (OR: 1.62; 95%CI: 1.11,2.37), higher Charlson Comorbidity Index (OR: 3.61; 95%CI: 1.69,7.71 for high scores), high MME/day at initiation (OR: 1.03; 95%CI: 1.02,1.03) and gabapentinoid (OR: 2.35; 95%CI: 1.75,3.16) and antidepressant use (OR: 1.69; 95%CI: 1.45,1.98). CONCLUSIONS: In AxSpA/PsA patients requiring pain relief, awareness of lifestyle, sociodemographic and prescribing characteristics associated with higher risk of long-term opioid use can prompt timely interventions such as structured medication reviews and smoking cessation to promote safer prescribing and better patient outcomes.
引用
- Huang YT, Jenkins DA, Yimer BB, et al. Factors associated with long-term opioid use among patients with axial spondyloarthritis or psoriatic arthritis who initiate opioids. Rheumatology (Oxford). 2025. PMID: 39150473. doi:10.1093/rheumatology/keae444
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。